• Explore /
  • Poster
  • / A randomized, double-blinded, controlled study of tucatinib (ONT-380) vs. placebo in combination with capecitabine (C) and trastuzumab (Tz) in patients with pretreated HER2+ unresectable locally advanced or metastatic breast carcinoma (mBC) (HER2CLIMB).

A randomized, double-blinded, controlled study of tucatinib (ONT-380) vs. placebo in combination with capecitabine (C) and trastuzumab (Tz) in patients with pretreated HER2+ unresectable locally advanced or metastatic breast carcinoma (mBC) (HER2CLIMB).

Abstract Poster

Authors

Carey Anders

Carey K. Anders

University of North Carolina, Chapel Hill, NC

Carey K. Anders , Rashmi Krishna Murthy , Erika Paige Hamilton , Virginia F. Borges , David A. Cameron , Lisa A. Carey , Volkmar Müller , Giuseppe Curigliano , Karen A. Gelmon , Gabriel N. Hortobagyi , Ian E. Krop , Sibylle Loibl , Xavier B. Pivot , Mark D. Pegram , Dennis J. Slamon , Sara A. Hurvitz , Michaela L. Tsai , Eric P. Winer

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Poster Details

Meeting

2017 ASCO Annual Meeting

Session Type

Poster Session

Session Title

Breast Cancer—Metastatic

Track

Breast Cancer

Sub Track

HER2-Positive

Clinical Trial Registration Number

NCT02614794

Citation

J Clin Oncol 35, 2017 (suppl; abstr TPS1107)

DOI

10.1200/JCO.2017.35.15_suppl.TPS1107

Abstract #

TPS1107

Poster Bd #

98b

Abstract Disclosures

Similar Posters

First Author: Giuseppe Curigliano

First Author: Ian E. Krop

First Author: Rashmi Krishna Murthy

First Author: Ian E. Krop